International cancer experts presented their findings for ovarian, esophageal cancer and Hodgkin lymphoma at the American Society of Clinical Oncology annual meeting.
(MedPage Today) -- CHICAGO -- The investigational CD40 agonist mitazalimab and modified FOLFIRINOX demonstrated encouraging activity in patients with previously untreated metastatic pancreatic ductal adenocarcinoma, according to the phase…
A new set of targeted and immune-boosting drugs can add months or even years to life expectancy according to results released this weekend at a top conference.
Pembrolizumab boosts the immune system’s ability to attack cancer. A study found that 59% of patients’ tumours shrank so much that there were no signs of disease when the affected section of their bowel was removed
Scaling back treatment for three kinds of cancer can make life easier for patients without compromising outcomes, doctors reported at the world's largest cancer conference.
(AP)–Scaling back treatment for three kinds of cancer can make life easier for patients without compromising outcomes, doctors reported at the world’s largest cancer conference. It’s part of a long-term trend toward studying whether doing…
Scaling back treatment for three kinds of cancer can make life easier for patients without compromising outcomes, doctors reported at the world’s largest cancer conference.
(MedPage Today) -- CHICAGO -- Early palliative care delivered via video was as effective as in-person visits on quality-of-life (QoL) measures among patients with advanced lung cancer, according to the REACH-PC trial.
By CARLA K. JOHNSON (AP Medical Writer) Scaling back treatment for three kinds of cancer can make life easier for patients without compromising outcomes, doctors reported at the world’s largest cancer conference. It’s part of a long-term…
An immunotherapy drug given before surgery instead of chemotherapy meant that over ten times more patients with a certain genetic profile were cancer-free after surgery, according to clinical trial results presented by researchers at UCL…